Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Subjects and a Comparison to Elderly Male and Female Subjects

The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.

Inclusion Criteria:

• Panels 1- 8 and Panels 14-15: healthy male subjects between the ages of 18 to 45
• Panels 9 and 10: healthy elderly males and females ages 60 and greater
• Panel 11: healthy males between the ages of 46-59
• Panel 12: males and/or females either healthy or with mild cognitive impairment (MCI) between the ages of 60 and 74
• Panel 13: males and/or females, healthy or with Alzheimer's disease (AD) or MCI that were 75 years of age or greater
• Acceptable medical history, physical examinations, vital signs, electrocardiograms, hemoccult stool tests, and clinical laboratory evaluations